UB Paderborn / Katalog / Suche / in CDI

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Journal of clinical oncology, 2022-10, Vol.40 (29), p.JCO2102614-3418

2022

Volltextzugriff (PDF)

Vascular thrombotic events in the era of modern myeloma therapy

British journal of haematology, 2022-12, Vol.199 (5), p.642-644

Mai, Elias Karl

2022

Volltextzugriff (PDF)

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Blood, 2016-09, Vol.128 (9), p.1226-1233

2016

Volltextzugriff (PDF)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

BMC cancer, 2023-11, Vol.23 (1), p.1-1132, Article 1132

2023

Volltextzugriff (PDF)

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma

Frontiers in oncology, 2022-07, Vol.12, p.919278-919278

2022

Volltextzugriff (PDF)

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

Leukemia, 2020-04, Vol.34 (4), p.1192-1196

2020

Volltextzugriff (PDF)

The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states

Journal of cancer research and clinical oncology, 2024-01, Vol.150 (2), p.55-55, Article 55

2024

Volltextzugriff (PDF)

Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma

European journal of nuclear medicine and molecular imaging, 2024, Vol.51 (8), p.2293-2307

2024

Volltextzugriff (PDF)

Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models

Journal of magnetic resonance imaging, 2024-05

2024

Volltextzugriff (PDF)

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Clinical cancer research, 2022-11, Vol.28 (21), p.4771-4781

2022

Volltextzugriff (PDF)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma

Frontiers in oncology, 2023-04, Vol.13, p.1078725-1078725

2023

Volltextzugriff (PDF)

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)

Cancers, 2023-10, Vol.15 (21), p.5157

2023

Volltextzugriff (PDF)

Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma

The FEBS journal, 2023-09, Vol.290 (17), p.4256-4267

2023

Volltextzugriff (PDF)

Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial

British journal of haematology, 2016-06, Vol.173 (5), p.731-741

2016

Volltextzugriff (PDF)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Blood cancer journal (New York), 2023-01, Vol.13 (1), p.1-1, Article 1

2023

Volltextzugriff (PDF)

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma

American journal of hematology, 2016-11, Vol.91 (11), p.E473-E477

2016

Volltextzugriff (PDF)

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma

Haematologica (Roma), 2015-06, Vol.100 (6), p.818

2015

Volltextzugriff (PDF)

Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation

British journal of haematology, 2022-01, Vol.196 (1), p.244-248

2022

Volltextzugriff (PDF)

Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma

Amyloid, 2024-06, Vol.31 (2), p.86-94

2024

Volltextzugriff (PDF)

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Clinical cancer research, 2020-11, Vol.26 (22), p.5879-5886

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Vascular thrombotic events in the era of modern myeloma therapy

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states

Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma

Genomic Classification and Individualized Prognosis in Multiple Myeloma

Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma

Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma

Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Suchergebnisse filtern